| |
|
|
| |
Management |
|
| |
|
|
| |
Dr. Hirth co-founded Plexxikon in December 2000, and has more than 25 years of biotechnology and pharmaceutical discovery and development experience. Previously, he was president of Sugen, Inc. until the sale of the company to Pharmacia Corporation in 1999. At Sugen, he helped build the company from its inception and advanced several kinase inhibitors through clinical trials for the treatment of oncology. Prior to Sugen, Dr. Hirth was a vice president in research with Boehringer Mannheim where, among other responsibilities, he successfully led the company's erythropoietin program. Previously, he also was a research scientist with the Max Planck Institute, following the completion of his post doctoral work at the University of California, San Diego. Dr. Hirth received his Ph.D. in molecular genetics from Heidelberg University, Germany.
Ms. Glaub joined Plexxikon in November 2001, responsible for corporate development, including business development, corporate communications, finance, and operations. She has more than 25 years of corporate development and financing experience, including over $4 billion in financing, merger and acquisition, and restructuring transactions. Since joining Plexxikon she has completed deals with Genentech, Wyeth, Servier and Roche. Prior to Plexxikon, Ms. Glaub served as an independent advisor to private companies for corporate development and financing. As senior vice president and chief financial officer of Cell Genesys, Ms. Glaub led a number of financings and strategic transactions, including the spin off and financing of Abgenix and the acquisition of Somatix Therapy Corporation. As treasurer of Genentech, Ms. Glaub led a number of financings, including R & D limited partnerships, a buyout of existing partnerships, and the industry's first convertible offering. Prior to Genentech, Ms. Glaub held various finance and treasury positions with Intel Corporation. Ms. Glaub received her M.B.A. in finance from Northwestern University.
Dr. Nolop joined Plexxikon in October 2004. He has 17 years of biotechnology and pharmaceutical clinical development experience, including the filing of multiple IND's, the successful filing of three new drug applications, and the approval of several labeling supplements. Prior to Plexxikon, he served as vice president of clinical research at CoTherix, Inc., where he was responsible for the clinical development of iloprost, a drug that has been accepted by the FDA for priority review. Prior to CoTherix, he was a senior director with Schering-Plough Corporation, where he successfully initiated early to late clinical programs in multiple disease indications including allergic rhinitis, asthma, COPD, and hypercholesterolemia. Dr. Nolop received his M.D. from Vanderbilt University and is board-certified in pulmonary diseases.
Dr. Artis has served as vice president, lead generation since November 2004, and has more than 20 years of chemistry, informatics and computer-aided drug design experience. He joined Plexxikon in April 2002 as senior director of informatics. Prior to Plexxikon, Dr. Artis held escalating positions with Genentech, most recently as senior scientist and head of the structural chemistry group, where he was responsible for directing computational approaches to the discovery and optimization of biomolecules using data from structural biology and informatics. Before Genentech, he held several positions as a staff researcher at Syntex, where he had primary responsibility for implementing the company's first major efforts in structure-guided drug design. He holds a Ph.D. in organic chemistry from Yale University.
Dr. Bollag has served as vice president of discovery biology since November 2004, and has more than 17 years of biotechnology drug discovery experience. He joined Plexxikon as senior director of drug discovery in June 2002. Prior to Plexxikon, he helped build drug discovery capabilities at Syrrx, Inc., where he was the director of cellular pharmacology. Before Syrrx, he held escalating positions at Onyx Pharmaceuticals, initially as one of the founding scientists and eventually senior director of small molecule therapeutics. While there, Dr. Bollag was involved in the Onyx collaboration with Bayer to discover BAY 43-9006, a kinase inhibitor that is now approved for the treatment of renal cell carcinoma and marketed under the trade name Nexavar®. Prior to Onyx, Dr. Bollag held various scientific positions at Cetus, Inc. Dr. Bollag earned his Ph.D. in biochemistry from the University of California, Berkeley.
Mr. Payne joined Plexxikon in August 2006, responsible for finance, accounting, facilities and information technology. He has over 20 years of corporate finance experience from Fortune 500, mid-sized, and start-up companies. He comes to Plexxikon from Rinat Neuroscience, where he was vice president of finance, responsible for all aspects of accounting, finance, information technology, operations, investor relations and facilities. At Rinat, he successfully led the finance negotiations and integration activities during Pfizer's acquisition of the company. Prior to Rinat, Mr. Payne held a variety of senior finance and treasury positions at Dynavax Technologies, Cell Genesys, Sun Microsystems and IBM Corporation. He has experience raising capital for both private and public companies, as well as experience in other strategic financial transactions and restructurings. Mr. Payne received his bachelor of science in business administration from the University of California Berkeley, Haas School of Business.
Dr. Visor joined Plexxikon in April 2007, responsible for managing pharmaceutical drug substance scale-up and manufacturing as well as dosage form design and development. He has more than 20 years of pharmaceutical and biotechnology manufacturing experience in process development, pharmaceutical operations, formulation and quality assurance. Prior to Plexxikon, he served as vice president, pharmaceutical research and process development and vice president of technical operations for OSI Pharmaceuticals where he was responsible for bulk API and drug product operations supporting oncology, metabolic and ophthalmology businesses. Previously, Dr. Visor held a variety of senior operations and development positions at leading biopharmaceutical companies including Cardinal Health, CellGate, Intermune, Roche Bioscience, Gilead Sciences, and Syntex Research. Dr. Visor received his Ph.D. in medicinal chemistry and pharmaceutical sciences from the University of Florida. |
|
| |
|
|
|
